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A 67-year-old man with castration-resistant prostate cancer associated with multiple bone metastases
had been treated with zoledronic acid and docetaxel. Although there was no evidence of damage around
the right lower jaw bone, the patient complained of pain in May 2011, which worsened during the next 2
weeks and was followed by difﬁculty with breathing. Computed tomographic (CT) ﬁndings of the cervical
area showed swelling of the cervical tissue with air and tightening of the trachea, suggesting cellulitis caused
by gas gangrene. He was intubated and treated with antibiotics. On the 12th hospital day, CT scan
revealed a pharyngeal abscess and we performed a drainage operation. On the 20th hospital day, bone of
the intraoral lower jaw was exposed, revealing that the infection was caused by osteonecrosis. Additional
CT ﬁndings showed the abscess extending to the mediastinum and multiple liver metastases. Although
antibiotic therapy was continued, the patient died of liver failure on the 61st day.
(Hinyokika Kiyo 59 : 587-591, 2013)













患 者 : 67歳，男性
主 訴 : 右下顎部痛
既往歴 : 糖尿病，高血圧
家族歴 : 特記事項なし
* 現 : 大阪大学大学院医学系研究科器官制御外科学
（泌尿器科）
現病歴 : 2009年 8 月，多発骨転移を伴う前立腺癌
（初診時 PSA 230 ng/ml，cT2bN0M1，stage IV) と診断
し，LH-RH アナログおよびビカルタミドによるアン
ドロゲン除去療法 (ADT) を開始した．その後 PSA
26.7 ng/ml まで低下したものの自己判断にて中止し，




ミドの内服などを行ったが，2011年 4 月，PSA 108
ng/ml まで上昇したため，2011年 5月上旬よりドセタ
キセル投与 (70 mg/m2) を開始した (Fig. 1）．この頃
から患者は右下顎部痛を訴えていたが，口腔外科では
異常を指摘されなかった．ドセタキセル投与 7日目，




入院時現症 : 血圧 121/76 mmHg，脈拍 90/分，
SpO2 98％ (room air），右下顎は著明に腫脹し圧痛を
伴っていた．
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Fig. 1. The treatment of prostate cancer and transition of PSA. DEX : dexamethasone,







Fig. 2. A : Cervical CT showed that the lower jaw was swollen (arrows) and the trachea
was constricted by the soft tissue (arrow heads). Gas was found in it (circles). B :
CT on day 12 showed retropharyngeal abscess (arrow heads). C : CT on day 23
showed mediastinitis (arrows).
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血液検査所見 : WBC 23,600/μl，RBC 318×104/μl，
Hb 10.3 g/dl，Ht 29.8％，Plt 25.4×104/μl，T-bil 0.6
mg/dl，AST 24 IU/l，ALT 27 IU/l，TP 5.8 g/dl，Alb
3. 0 g/dl，BUN 75 mg/dl，CRE 5. 32 mg/dl，Na 136
mEq/l，K 4.3 mEq/l，Cl 102 mEq/l，Ca 6.0 mg/dl，
IP 3. 8 mg/dl，CRP 30. 8 mg/dl，HbA1c (JDS 値）
5.3％．
血液ガス所見 : pH 7. 376，PaO2 87. 8 mmHg，






















Fig. 3. Clinical course of the patient after admission. SBT/CPZ : sulbactam cefoperazone, CLDM :
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BRONJ の診断基準は，「○1 現在あるいは過去に BP
製剤による治療歴があること，○2口腔・顎・顔面領域
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